Introduction
The Core Binding Factor (CBF) family consists of heterodimeric transcription factors that contain a common CBFb subunit and one of three CBFa subunits, CBFa1, AML1 (CBFa2), or CBFa3 (Bae et al., 1993; Wang et al., 1993; Ogawa et al., 1993a,b; Levanon et al., 1994) . The CBFa subunits have a Runt-homology domain required for heterodimerization and DNA-binding (Bae et al., 1993; Meyers et al., 1993) . CBFb does not bind DNA, but increases the DNA-anity of the CBFa subunits (Wang et al., 1993; Ogawa et al., 1993b) . CBF has both trans-activating and trans-repressing activities (Redondo et al., 1992; Ogawa et al., 1993a; Suzow and Friedman, 1993; Imai et al., 1998; Levanon et al., 1998; Fenrick et al., 1999) .
Translocations involving the AML1 or CBFb genes are common in acute leukemias (Friedman, 1999) . In acute myeloid leukemia (AML), t(8;21), t(3;21), and inv(16) encode AML1-ETO, AML1-MDS1/EVI1, and CBFb-SMMHC, respectively, and in acute lymphocytic leukemia t(12;21) encodes TEL-AML1 (Miyoshi et al., 1993; Liu et al., 1993; Nucifora et al., 1993; Golub et al., 1995; Romana et al., 1995) . Each of these CBF oncoproteins inhibit CBF trans-activation in cell lines (Liu et al., 1994; Meyers et al., 1995; Hiebert et al., 1996; Zent et al., 1996; Cao et al., 1998) . Also, mice expressing AMLI-ETO or CBFb-SMMHC and mice lacking AML1 or CBFb each fail to develop de®nitive hematopoiesis, indicating that these CBF oncoproteins inhibit CBF activities in vivo as well (Castilla et al., 1996; Okuda et al., 1996; Sasaki et al., 1996; Wang et al., 1996a,b; Yergeau et al., 1997) . The relevance of CBF inhibition for leukemogenesis is supported by the ®nding that four of 90 AMLs lacking inv(16) or t(8;21) carry mutations which result in the expression of AML1 variants defective for DNA-binding or lacking its C-terminal trans-activation domains and by the ®nding of CBFA2 haploinsuciency in familial platelet disorder with predisposition to AML (Osato et al., 1999; Song et al., 1999) .
When expressed inducibly from the sheep metallothionein (MT) promoter in IL-3-dependent 32D cl3 myeloid or Ba/F3 B-lymphoid cells, CBFb-SMMHC interferes with CBF DNA-binding, slows cell proliferation, and increases the ratio of G1 phase to S phase cells threefold (Cao et al., 1997) . CBFb-SMMHC may sequester endogenous CBFa subunits in complexes that form as a result of multimerization via its Smooth Muscle Myosin Heavy Chain (SMMHC) domain or as a result of interaction with cytoskeletal proteins Tanaka et al., 1998) . Deletion of 11 CBFb-SMMHC N-terminal amino acids required for interaction with CBFa subunits prevented its inhibition of CBF DNA-binding, CBF trans-activation, and cell proliferation . These results suggest that CBF regulates the G1 to S transition. However, CBFb interacts with the cytoskeleton (Tanaka et al., 1997) and perhaps other proteins, and the SMMHC domain likely interacts with non-muscle myosins and perhaps other coiled-coil proteins.
We now provide additional evidence indicating that CBF regulates G1 and, moreover, that this activity is dependent upon CBF's ability to stimulate rather than to repress transcription. First, KRAB-AML1-ER, containing the potent KRAB repression domain (Margolin et al., 1994) and the AML1 DNA-binding domain, markedly inhibited cell proliferation in the presence of 4-hydroxytamoxifen (4HT). And second, activation of AML1-ER, containing the entire AML1B protein, overcame CBFb-SMMHC-induced growth inhibition.
These observations suggest that mutations which accelerate G1 might overcome inhibition of proliferation by CBF oncoproteins. In fact, the genes encoding p15 are frequently inactivated by methylation in acute leukemias (Herman et al., 1996) . Using Representational Dierence Analysis (RDA) and Northern blotting, we demonstrate that CBFb-SMMHC or KRAB-AML1 reduce cdk4 RNA levels several-fold in 6 ± 24 h, even when growth inhibition is prevented by exogenous cdk4.
Results
Transcriptional repression via CBF DNA-binding sites slows proliferation during G1
We assembled a cDNA linking a KRAB transrepression domain, the AML1 DNA-binding domain, and a modi®ed human Estrogen Receptor ligandbinding domain (ER) which responds to 4HT but not estradiol (Littlewood et al., 1995) (Figure 1a, left) . A variant lacking 18 residues in the AML1 Runt domain required for DNA-binding was also constructed. KRAB-AML1-ER inhibited trans- 4 cells/ml, 7 or +4HT, and the ratios of viable cell counts 48 h later are shown (right, mean and s.e. of two determinations). (c) The indicated lines were cultured in 4HT for 0, 1, or 2 days, pulsed for 30 min with 30 mM BrdU, ®xed, stained with anti-BrdU-FITC and propidium iodide (PI), and subject to FACScan analysis. Representative staining patterns from duplicate experiments are shown, as are the locations of the cells in the G1, S, and G2/M cell cycle phases activation of p(CBF) 4 TKLUC by AML1-VP16 sixfold in NIH3T3 cells, whereas KRAB-DAML1-ER was ineective (Figure 1a, right) . Stable, puromycinresistant Ba/F3 lines expressing these proteins were obtained by retroviral transduction (Figure 1b, left) . CB6 is an untransduced control line containing the MTCB6 vector (Cao et al., 1997) . When Ba/F3-KRAB-AML1-ER cells were exposed to 4HT, their proliferation slowed dramatically (Figure 1b, right) . Decreased proliferation was associated with a marked G1/S cell cycle arrest, and a modest G2/M arrest, but not prominent apoptosis (Figure 1c) . In two experiments, 4HT did not aect the cell cycle pro®le of MTCB6 cells over a 48 h period, but shifted the G1/S ratio from 0.4 to 3.0 or 9.4 in the two KRAB-AML1-ER lines. Retinoblastoma protein (Rb) became relatively hypophosphorylated, as occurred when CBFb-SMMHC was expressed in Ba/F3 or 32D cl3 cells (Cao et al., 1997) , p21 levels were not aected, and p27 levels became elevated (not shown). Ba/F3-KRAB-AML1-ER lines could be cultured for more than 2 months without diminution in KRAB-AML1-ER levels or cell cycle inhibition in response to 4HT, suggesting that this protein is not leaky and does not exert selective pressure on the cells.
32D cl3 lines expressing KRAB-AML1-ER were also obtained (Figure 2a, left) . Their proliferation in IL-3 or G-CSF was greatly reduced upon exposure to 4HT (Figure 2a, right) , and activation of KRAB-AML1-ER prevented G-CSF-induced induction of MPO mRNA ( Figure 2b ). In IL-3, no morphologic dierentiation of 32D-KRAB-AML1-ER cells exposed to 4HT was evident, and in G-CSF cell death occurred by day 3 without the development of a neutrophilic morphology (not shown). Thus, inhibition of CBF activities interferes with granulocytic dierentiation as well as cell cycle progression.
Exogenous AML1 overcomes CBFb-SMMHC inhibition of proliferation
To further examine the role of AML1 in the regulation of proliferation, we developed a fusion protein between the AML1B isoform of AML1 and the 4HT-responsive ER ligand-binding domain (Figure 3a , left). An 8 amino acid segment, GPNASPNS, was included between the AML1B and the ER domains. AML1-ER activated p(CBF) 4 TKLUC 2.3-fold (Figure 3a , right). pBabePuro-AML1-ER was transduced into Ba/ F3 and Ba/F3-MTINV-3 cells. MTINV-3 cells are neomycin-resistant and express a high-level of CBFb-SMMHC when exposed to zinc (Cao et al., 1997) . Subclones expressing AML1-ER were identi®ed by Western blotting (Figure 3b , top). MTINV-3 cells expressing AML1-ER retained high levels of CBFb-SMMHC (Figure 3b , top). Activation of AML1-ER by 4HT did not accelerate the growth rate of Ba/F3 or Ba/F3-MTINV cells cultured in the absence of zinc (Figure 3b , bottom). Exposure of the Ba/F3-MTINV/ AML1-ER pool or subclones to zinc slowed their proliferation 3 ± 5-fold over 72 h, but addition of 4HT obviated this growth inhibition (Figure 3b, bottom) . Cell cycle analysis demonstrated that AML1-ER reversed CBFb-SMMHC-induced inhibition of G1 progression ( Figure 3c ). Of note, treatment of these lines with 4HT alone reproducibly increased the proportion of cells in S phase 5 ± 15%, although the cells actually proliferated at a mildly reduced rate ( Figure 3b ). The increased proportion of cells in S phase may re¯ect acceleration of G1, as recently described for 32D cl3 cells stably expressing exogenous AML1B (Strom et al., 2000) . These 32D-AML1B lines do not have an accelerated rate of proliferation ± this ®nding and the mild slowing we observe may re¯ect compensatory eects of other regulatory proteins.
Inhibition of CBF decreases cdk4 levels
Ba/F3-KRAB-AML1-ER and Ba/F3-KRAB-DAML1-ER cells were exposed to 4HT for 6 h. Poly Acontaining mRNA was then prepared and subjected to RDA, either using RNA from the KRAB-AML1-ER or the KRAB-DAML1-ER line as driver (Figure 4 ). After two rounds of RDA, unique band patterns emerged. To identify RNAs repressed by KRAB-AML1, the four major bands evident in the R2 sample were isolated and several subclones of each band were sequenced (Table 1) . Band`a' represents Hsp73, which may signify an artifact of our system as the ER domain interacts with the very closely related Hsp70 protein (Smith and Toft, 1993) . Band`b' includes a clone for 4 cells/ml in IL-3 or G-CSF. Viable cell counts 48 h later are shown (right, mean and s.e. from two determinations). (b) 32D-KRAB-AML1-ER-2 cells were transferred from IL-3 to G-CSF for 0, 6, 24, or 48 h in the absence or presence of 4HT. Total cellular RNAs prepared at these times were subjected to Northern blotting for myeloperoxidase (MPO), b5-tubulin (Tub), and 18S RNAs an RNA polymerase II-binding protein (Yuryev et al., 1996) and a clone for subunit of RNA polymerase III (Sepehri and Hernandez, 1997) , both of which potentially regulate cell proliferation. Another clone isolated from band`b' encodes fau, an arsenateresistance protein which is also a tumor suppressor (Rossman and Wang, 1999) . Band`d' encodes ribosomal protein L26 (Segade et al., 1996) , and all six subclones of band`c' derives from the cdk4 mRNA.
As cdk4 is a known regulator of the G1 cell cycle phase, we sought to determine the eect of CBF inhibition on its expression. Activation of KRAB-AML1-ER or induction of CBFb-SMMHC in Ba/F3 cells decreased cdk4 RNA and protein levels as early as 6 h whereas similar treatment of the parental Ba/F3, KRAB-DAML1-ER or MTCB6 control lines did not alter cdk4 RNA or protein levels ( Figure 5, Figure 6a , lanes 1 and 2, and not shown). Inhibition of cdk4 expression was reversible (not shown).
Exogenous cdk4 overcomes inhibition of proliferation from reduced CBF trans-activation
The murine cdk4 cDNA was introduced into pBabeNeo, and the resulting vector was transduced into Ba/ F3 or Ba/F3-KRAB-AML1-ER cells. We identi®ed two G418-resistant Ba/F3-KRAB-AML1-ER lines (cdk4-1, cdk4-2) with a several-fold increase in cdk4 levels. Addition of 4HT for 24 h did not induce a decrease in total cdk4 protein in these lines, whereas addition of 4HT to the initial KRAB-AML1-ER line resulted in a large decrease in cdk4 (Figure 6a ). Exogenous cdk4 did not aect the proliferation rate Representational Dierence Analysis (RDA) to identify CBF genetic targets. RNAs from Ba/F3-KRAB-AML1-ER and Ba/F3-KRAB-DAML1-ER cells exposed to 4HT for 6 h were converted to Driver (D) and Tester (T) cDNAs. The products of rounds one and two of RDA, using the KRAB-AML1-ER population as Driver (R1, R2) or using the KRAB-DAML1-ER population as Driver (rR1, rR2) are shown. a ± d denote prominent bands in the R2 sample. M7molecular weight markers (Figure 4) were sequenced. The corresponding GenBank accession numbers are shown of Ba/F3 cells or of the double transfectants cultured in the absence of 4HT (not shown). Cdk4 reduced growth inhibition by KRAB-AML1-ER from 5.2 to 1.4-fold in cdk4-1 cells and to 2.8-fold in cdk4-2 cells ( Figure 6 ). Of note, greater protection was seen in cdk4-1 cells, which at 24 h express more cdk4 than do cdk4-2 cells, relative to actin. We also identi®ed three Ba/F3-KRAB-AML1-ER subclones, from the same transduction, in which cdk4 levels decreased to near control levels in response to 4HT. Activation of KRAB-AML1-ER in these lines slowed proliferation more than ®vefold over 48 h (not shown). KRAB-AML1-ER, KRAB-AML1-ER/cdk4-1, and KRAB-AML1-ER/cdk4-2 cells were subjected to cell cycle analysis in the presence or absence of 4HT (Figure 6c ). The G1/ S ratio for the parental line increased 14-fold in response to 4HT, whereas when cdk4 was co-expressed the G1/S ratios increased only 1.2-or 1.7-fold. As cdk4 did not completely overcome growth inhibition resulting from reduced CBF trans-activation, we also co-expressed a cdk4 variant, cdk4(R24C), with KRAB-AML1-ER. This variant does not interact with p16
INK4a (Zuo et al., 1996) . Cdk4(R24C) completely prevented growth inhibition by KRAB-AML1-ER (Figure 6d ).
Cdk4-1 and cdk4-2 cells express KRAB-AML1-ER at or near the level of the parental KRAB-AML1-ER line, if gel loading is taken into account (Figure 6b ). In contrast, the cdk4(R24C) lines expressed 2 ± 3-fold less KRAB-AML1-ER (not shown). Whether this is an indirect eect of cdk4(R24C) is not clear. We therefore generated a series of Ba/F3 lines with a range of KRAB-AML1-ER levels, including several with levels similar to those detected in the cdk4(R24C) subclones. Activation of KRAB-AML1-ER potently inhibited the proliferation of each of these lines (not shown).
CBF inhibition reduces endogenous cdk4 RNA in cells proliferating near control rates
To determine the eect of exogenous cdk4 on the regulation of endogenous cdk4 by CBF, RNA was prepared from Ba/F3-KRAB-AML1-ER/cdk4-1 cells 0, 6, 24, and 48 h after exposure to 4HT, using the same culture from which proteins were prepared for the Western blot in Figure 6a . These RNAs were subjected to Northern blotting and probed for the cdk4 and 18S RNAs (Figure 7) . Despite a nearly normal growth rate, endogenous cdk4 RNA was decreased by 24 h, whereas the level of exogenous cdk4 RNA remained unchanged. Prior to addition of 4HT, the levels of endogenous and exogenous cdk4 RNA were similar, although cdk4 protein is increased several-fold in this line compared to Ba/F3-KRAB-AML1-ER cells (Figure 6b ). This may re¯ect increased translation eciency from the exogenous RNA. Of note, 4HT restored basal expression of cdk4 RNA in INV/AML1-ER cells exposed to zinc, but did not increase expression of cdk4 in these cells in the absence of zinc (not shown).
Discussion
CBFb-SMMHC prevents the development of de®nitive hematopoiesis during murine embryogenesis and obviates the formation of lymphoid and myeloid cells in adult mice (Castilla et al., 1996 (Castilla et al., , 1999 . The ability of CBFb-SMMHC to inhibit cell cycle progression might account for these phenotypes (Cao et al., 1997) . Two additional lines of evidence described herein also indicate that CBF regulates the G1 to S transition: An arti®cial repressor of CBF trans-activation, KRAB-AML1-ER, slows proliferation during G1, and exogenous AML1 reverses CBFb-SMMHC-induced cell cycle inhibition. These eects are not restricted to use of the KRAB repression domain, as an AML1-ETO-ER fusion containing the central ETO repression domain, but lacking the ETO C-terminus, had similar activities (not shown).
AML1B both activates and represses transcription (Ogawa et al., 1993a; Fenrick et al., 1999) . Our results indicate that CBF trans-activation is required for optimal G1 progression. If trans-repression was more critical, KRAB-AML1-ER would not be expected to inhibit proliferation.
If CBF oncoproteins inhibit cell proliferation, how do they contribute to leukemogenesis? The ®nding that the proximal enhancer of MPO, an early-myeloidspeci®c gene, is regulated by CBF supported the idea that CBFb-SMMHC or AML1-ETO inhibit myeloid dierentiation (Suzow and Friedman, 1993; Nuchprayoon et al., 1994) . Consistent with this model, we demonstrate that KRAB-AML1-ER inhibits endogenous MPO mRNA expression in dierentiating 32D cl3 cells.
Activation of KRAB-AML1-ER did not alter expression of exogenous cdk4 RNA and caused either no change or a mild decrease in KRAB-AML1-ER protein levels, suggesting that the MMLV LTR is not strongly repressed by this factor, even though it is activated by CBF (Wang et al., 1993) . In contrast to MPO, other factors which activate the LTR may compensate for repression by KRAB-AML1-ER. Similarly, all CBF-regulated genes may not be repressed by CBF oncoproteins.
Inhibition of G1 progression by CBFb-SMMHC or KRAB-AML1 suggests that mutations which accelerate G1 might overcome inhibition of proliferation by CBF oncoproteins. Expression of either CBFb-SMMHC or KRAB-AML1-ER results in Rb hypophosphorylation, indicating that a gene encoding a regulatory protein acting at or prior to the restriction point is activated by CBF. Results of RDA and subsequent Northern analyses indicate that cdk4 RNA expression decreases rapidly upon activation of KRAB-AML1-ER. Reduction in cdk4 RNA levels was not secondary to decreased proliferation rate, as this occurred also in cells expressing exogenous cdk4 and so largely insensitive to KRAB-AML1-mediated growth inhibition. We intend to utilize available genomic clones for the human and murine cdk4 genes to explore the possibility that the cdk4 promoter region is directly activated by CBF. The human cdk4 gene (GeneBank #U81031) has a consensus CBF-binding site at 7986 and several sites which dier from the consensus by 1 bp within 1 kb of the RNA start site. RDA analysis also identi®ed several additional clones which are likely required for optimal cell proliferation and which may represent genetic targets of CBF (Table  1) .
Regardless of whether the cdk4 gene is directly or indirectly regulated by CBF, we sought to determine whether exogenous cdk4 would by-pass inhibition of proliferation by KRAB-AML1-ER. Cdk4 almost completely prevented inhibition in one line and partially overcame growth inhibition in a second. Also, co-expression of a cdk4 variant incapable of interacting with p16
INK4a restored the rate of G1 progression to that evident in parental cells. Exogenous cyclin D2 also prevented KRAB-AML1-ER from inhibiting Ba/F3 proliferation (not shown). Exogenous cdk4 or cyclin D2 prevent 32D cl3 cell dierentiation (Kato and Sherr, 1993 , and data not shown), and so we could not use these cells to assess the ability of these proteins to potentiate inhibition of dierentiation by AML1-ETO or CBFb-SMMHC. However, having demonstrated that proteins which stimulate G1 by-pass cell cycle inhibition mediated by KRAB-AML1, we intend to test whether analogous genetic alterations cooperate with CBF oncoproteins in vivo to induce acute leukemias. The recent ®nding that the human and murine cdk4 genes are activated by c-Myc suggests that this protein could cooperate with CBF oncoproteins in leukemogenesis (Hermeking et al., 2000) .
Materials and methods
Cell culture, proliferation assays, and retroviral transduction Ba/F3 cells were maintained in RPMI 1640 with 10% heatinactivated fetal calf serum (HI-FCS) and 1 ng/ml IL-3 (R&D Systems, Minneapolis, MN, USA). 32D cl3 cells were maintained in Iscove's modi®ed Dulbecco's medium (IMDM) with 10% HI-FCS, and IL-3. jCRE (Danos and Mulligan, 1988) and NIH-3T3 cells were cultured in Dulbecco's modi®ed Eagle's medium with 10% heat-inactivated calf serum. When necessary, 32D cl3 cells were washed twice with phosphate-buered saline and transferred to IMDM with 10% HI-FCS and 1000 U/ml G-CSF (Amgen, Thousand Oaks, CA, USA). Viable cells were determined by enumerated cells that excluded Trypan Blue dye. BrdU/PI staining and FACScan analysis were performed as described (Cao et al., 1997) . Zinc chloride was employed at 100 mM, and 4HT was employed at 200 nM. Retroviral vectors were packaged using calcium phosphate precipitation followed 48 h later by dilution of jCRE cells into either 1 mg/ml G418 or 2 mg/ml puromycin. For retroviral transduction, subcon¯uent pools of packaging cells were irradiated to 3000 cGy and co-cultured with Ba/F3 or 32D cl3 lines in their growth media for 48 h with 8 mg/ml Polybrene. Subclones were isolated by limiting dilution using 96-well dishes.
Plasmids and transient transfection assays
The KRAB-AML1-ER cDNA was constructed by linking cDNA segments encoding amino acids 1 ± 89 of KOX1 (Margolin et al., 1994) , amino acids 59 ± 185 of human AML1B (SmaI to BclI), and the tamoxifen-responsive ER domain.
5'-GGATCCGGGGTACCCGGCGCTGTC-3' serves as a linker between the KRAB and AML1 cDNA segments. This cDNA was then ligated into the pBabePuro polylinker as a SnaB1/SalI fragment. PCR mutagenesis followed by DNA sequencing was employed to delete AML1 amino acids 59 ± 76 in KRAB-AML1-ER, along with ®ve of the eight residues encoded by the 24 bp segment between the KRAB and AML1 domains, to generate pBabe-KRAB-DAML1-ER-puro. The AML1 cDNA contains a BssHII site starting 33 bp 5' to its stop codon. An oligonucleotide containing these 33 bp followed by a 24 bp linker, 5'-GGGCCTGACGCGTCTCCCAATTCT-3', was positioned between an EcoRI/BssHII fragment encoding residues 1 ± 469 of AML1 and the ER domain to generate the AML1-ER cDNA. This cDNA was then inserted into BabePuro as an EcoRI/SalI fragment. The murine cdk4 cDNA (Matsushime et al., 1992) , was ligated into the EcoRI site of pBabeNeo. pBabeNeo-cdk4(R24C) was constructed by changing codon 24 from CGA to TGT by inserting a 27 bp oligonucleotide containing this mutation between the¯anking BsrG1 and MscI sites in the murine cdk4 cDNA. p(CBF) 4 TKLUC contains 4 CBF sites derived from the MPO gene and a minimal thymidine kinase promoter, and pAML1-VP16 contains the AML1 DNA-binding domain and the VP16 trans-activation domain . NIH3T3 cells were transiently transfected with calcium phosphate-DNA precipitates, subjected to 15% glycerol/PBS shock for 3.5 min at 18 h, and harvested at 48 h. CMV-bGal was included as an internal control. Luciferase and b-galactosidase assays were performed as described .
Western and Northern blotting
Preparation of total cellular protein and RNA, Western blotting, Fast Green staining, Northern blotting, and ®lter stripping were performed as described . ERa (MC-20) and cdk4 (H-22) antisera were obtained commercially (Santa Cruz Biotech., Santa Cruz, CA, USA), as was the b-actin antibody AC-15 (Sigma, St. Louis, MO, USA), and an antisera recognizing CBFb-SMMHC was kindly provided by N Speck.
Representational Difference Analysis (RDA)
PolyA-containing RNA was prepared from Ba/F3-KRAB-AML1-ER or Ba/F3-KRAB-DAML1-ER cells exposed to 4HT for 6 h using an mRNA isolation kit (Stratagene, San Diego, CA, USA). These mRNAs were then converted to cDNA and subjected to RDA as described (Lewis et al., 1997) . In brief, the oligo-dT primed cDNAs were ampli®ed by PCR after linker ligation and digested with DpnII to generate Driver and Tester populations. The ®rst linker was removed, a second linker was ligated to the Tester, and round one of RDA was performed at a 100 : 1 D : T ratio. The second linker was then removed, a third linker ligated to the Tester, and round two of RDA performed at 800 : 1. For reverse RDA, the population used initially as Driver was used as Tester. RDA products were visualized with ethidium bromide staining after resolution on a 1.5% agarose gel. Discrete bands were isolated, digested with BamHI, and subcloned into similarly digested pBS. Inserts were subjected to dideoxy-nucleotide sequencing. 
